🚀 VC round data is live in beta, check it out!
Acrivon Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Acrivon Therapeutics and similar public comparables like PDS Biotechnology, TScan Therapeutics, Cantourage Group, Arovella Therapeutics and more.
Acrivon Therapeutics Overview
About Acrivon Therapeutics
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Founded
2018
HQ
Employees
78
Website
Sectors
Financials (LTM)
Market Cap
$60M
Acrivon Therapeutics Financials
Acrivon Therapeutics reported last 12-month revenue of $411K.
In the same LTM period, Acrivon Therapeutics generated $339K in gross profit and had net loss of ($81M).
Revenue (LTM)
Acrivon Therapeutics P&L
In the most recent fiscal year, Acrivon Therapeutics reported revenue of — and EBITDA of ($83M).
Acrivon Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $411K | XXX | — | XXX | XXX | XXX |
| Gross Profit | $339K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($83M) | XXX | XXX | XXX |
| EBIT Margin | (21066%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($81M) | XXX | ($78M) | XXX | XXX | XXX |
| Net Margin | (19652%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Acrivon Therapeutics Stock Performance
Acrivon Therapeutics has current market cap of $60M.
Market Cap Evolution
Acrivon Therapeutics' stock price is $1.56.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $60M | 2.0% | XXX | XXX | XXX | $-2.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAcrivon Therapeutics Valuation Multiples
Acrivon Therapeutics trades at (134.8x) EV/Revenue multiple, and 0.7x EV/EBITDA.
EV / Revenue (LTM)
Acrivon Therapeutics Financial Valuation Multiples
As of April 11, 2026, Acrivon Therapeutics has market cap of $60M.
Equity research analysts estimate Acrivon Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Acrivon Therapeutics has a P/E ratio of (0.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $60M | XXX | $60M | XXX | XXX | XXX |
| EV (current) | ($55M) | XXX | ($55M) | XXX | XXX | XXX |
| EV/Revenue | (134.8x) | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBIT | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| EV/Gross Profit | (163.4x) | XXX | — | XXX | XXX | XXX |
| P/E | (0.7x) | XXX | (0.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Acrivon Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Acrivon Therapeutics Margins & Growth Rates
Acrivon Therapeutics' revenue in the last 12 month grew by 418%.
Acrivon Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.1M for the same period.
Acrivon Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 418% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (6%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5760% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15117% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Acrivon Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| PDS Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| TScan Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cantourage Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| BGM Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acrivon Therapeutics M&A Activity
Acrivon Therapeutics acquired XXX companies to date.
Last acquisition by Acrivon Therapeutics was on XXXXXXXX, XXXXX. Acrivon Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Acrivon Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAcrivon Therapeutics Investment Activity
Acrivon Therapeutics invested in XXX companies to date.
Acrivon Therapeutics made its latest investment on XXXXXXXX, XXXXX. Acrivon Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Acrivon Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Acrivon Therapeutics
| When was Acrivon Therapeutics founded? | Acrivon Therapeutics was founded in 2018. |
| Where is Acrivon Therapeutics headquartered? | Acrivon Therapeutics is headquartered in United States. |
| How many employees does Acrivon Therapeutics have? | As of today, Acrivon Therapeutics has over 78 employees. |
| Who is the CEO of Acrivon Therapeutics? | Acrivon Therapeutics' CEO is Peter Blume-Jensen. |
| Is Acrivon Therapeutics publicly listed? | Yes, Acrivon Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Acrivon Therapeutics? | Acrivon Therapeutics trades under ACRV ticker. |
| When did Acrivon Therapeutics go public? | Acrivon Therapeutics went public in 2022. |
| Who are competitors of Acrivon Therapeutics? | Acrivon Therapeutics main competitors are PDS Biotechnology, TScan Therapeutics, Cantourage Group, Arovella Therapeutics. |
| What is the current market cap of Acrivon Therapeutics? | Acrivon Therapeutics' current market cap is $60M. |
| What is the current revenue of Acrivon Therapeutics? | Acrivon Therapeutics' last 12 months revenue is $411K. |
| What is the current revenue growth of Acrivon Therapeutics? | Acrivon Therapeutics revenue growth (NTM/LTM) is 418%. |
| What is the current EV/Revenue multiple of Acrivon Therapeutics? | Current revenue multiple of Acrivon Therapeutics is (134.8x). |
| Is Acrivon Therapeutics profitable? | No, Acrivon Therapeutics is not profitable. |
| What is the current net income of Acrivon Therapeutics? | Acrivon Therapeutics' last 12 months net income is ($81M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.